We are proud to share that our latest case report has been published in Frontiers in Oncology!
In this study, we describe a patient with advanced-stage prostate cancer and extensive bone metastases who responded positively to our personalized peptide-based immunization therapy (BITAP). Administered as a monotherapy, BITAP was associated with regression of both metastatic and primary tumor lesions, stabilization of PSA levels, and only mild, short-term side effects.
This case underscores the potential of personalized peptide immunization as a promising therapeutic approach for treatment-resistant prostate cancer.
We are deeply grateful to everyone who helped make this work possible.
Back to all updates